Scholar Rock shares are up about 3% in Tuesday trading, extending a post-resubmission bid as investors refocus on the company’s lead asset, apitegromab, and its regulatory path in spinal muscular atrophy (SMA). There was no new company newsroom item dated April 28, suggesting the move is being driven by continued digestion of the late-March regulatory reset and positioning into the next FDA milestone rather than a brand-new headline.

On March 31, 2026, Scholar Rock resubmitted its Biologics License Application to the FDA for apitegromab in SMA, and outlined expectations for FDA acceptance within 30 days and a review timeline of up to six months from resubmission. The company framed the potential FDA action date as late September 2026, effectively putting a visible, date-certain catalyst back on the calendar after prior manufacturing-related delays.

For a late-stage biotech with a single, highly watched lead program, a clear regulatory timeline can tighten the investment narrative and improve risk-on sentiment, particularly after prior uncertainty tied to third-party manufacturing. With the review path clarified and the decision window approaching later this year, incremental buying can emerge on quiet news days as investors rebuild exposure ahead of key FDA milestones.

Traders will be keyed to (1) formal FDA acceptance/filing updates, (2) any commentary around manufacturing readiness given prior issues at a third-party site, and (3) any updates that shift the expected late-September 2026 action timing. Any confirmation that the submission is progressing cleanly, or any indication of additional manufacturing scrutiny, could move the stock sharply in either direction.